Berlin-Karlshorst

Germany

3 total trials

Filter these 3 trials by phase, condition, sponsor and more.

Open in Search →

Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Crohn's Disease Ended recruitment

2023-504741-32-00 4 2022-11-30 Moderately to Severely Active Crohn's Disease
Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colit … Ended recruitment

2023-504743-13-00 4 2022-11-30 Moderately to Severely Active Ulcerative Colitis
GRAVITI - A Phase 3 Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately t … Ended recruitment

2023-504737-41-00 5 2022-06-10 Moderately to Severely Active Crohn's Disease

Showing 1–3 of 3 trials